Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Lung Cancer

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 37 articles:
HTML format



Single Articles


    July 2021
  1. ROHRICH M, Leitz D, Glatting FM, Wefers AK, et al
    Fibroblast Activation Protein specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261925. doi: 10.2967/jnumed.121.261925.
    PubMed     Abstract available


  2. NIEMEIJER AN, Oprea Lager DE, Huisman MC, Hoekstra OS, et al
    First-in-human study of (89)Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261926. doi: 10.2967/jnumed.121.261926.
    PubMed     Abstract available


    May 2021
  3. GUBERINA M, Poettgen C, Metzenmacher M, Wiesweg M, et al
    PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.
    J Nucl Med. 2021 May 20. pii: jnumed.120.260646. doi: 10.2967/jnumed.120.260646.
    PubMed     Abstract available


    January 2021
  4. LAFFON E, Marthan R
    Distribution Volume of (18)F-BMS-986192 in NSCLC Patients.
    J Nucl Med. 2021;62:144.
    PubMed    


    December 2020
  5. STUSCHKE M, Pottgen C
    (18)F-FDG PET/CT for Target Volume Contouring in Lung Cancer Radiotherapy.
    J Nucl Med. 2020;61.
    PubMed    


    November 2020
  6. AYATI N, Lee ST, Zakavi SR, Cheng M, et al
    Response evaluation and survival prediction following PD-1 immunotherapy in patients with non-small-cell lung cancer: comparison of assessment methods.
    J Nucl Med. 2020 Nov 27. pii: jnumed.120.254508. doi: 10.2967/jnumed.120.254508.
    PubMed     Abstract available


    October 2020
  7. CHRISTENSEN TN, Langer SW, Persson GF, Larsen KR, et al
    (18)F-FLT-PET/CT adds value to (18)F-FDG-PET/CT for diagnosing relapse after definitive radiotherapy in patients with lung cancer. Results of a prospective clinical trial.
    J Nucl Med. 2020 Oct 9. pii: jnumed.120.247742. doi: 10.2967/jnumed.120.247742.
    PubMed     Abstract available


    September 2020
  8. GALLDIKS N, Abdulla DS, Scheffler M, Wolpert F, et al
    Treatment Monitoring of Immunotherapy and Targeted Therapy using (18)F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences.
    J Nucl Med. 2020 Sep 4. pii: jnumed.120.248278. doi: 10.2967/jnumed.120.248278.
    PubMed     Abstract available


  9. CASTELLO A, Lopci E
    Reply: Diagnosis of Hyperprogressive Disease in Patients Treated with Checkpoint Inhibitors Using (18)F-FDG PET/CT.
    J Nucl Med. 2020;61:1405.
    PubMed    


    June 2020
  10. GIESEL F, Adeberg S, Syed M, Lindner T, et al
    FAPI-74 PET/CT Using Either (18)F-AlF or Cold-kit (68)Ga-labeling: Biodistribution, Radiation Dosimetry and Tumor Delineation in Lung Cancer Patients.
    J Nucl Med. 2020 Jun 26. pii: jnumed.120.245084. doi: 10.2967/jnumed.120.245084.
    PubMed     Abstract available


  11. FERDINANDUS J, Barbato F, Chodyla M, Fendler WP, et al
    Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma.
    J Nucl Med. 2020 Jun 12. pii: jnumed.120.245803. doi: 10.2967/jnumed.120.245803.
    PubMed     Abstract available


    April 2020
  12. REYNOLDS JC, Maass-Moreno R, Thomas A, Ling A, et al
    FDG-PET assessment of malignant pleural mesothelioma: Total Lesion volume and Total Lesion Glycolysis; the central role of volume.
    J Nucl Med. 2020 Apr 13. pii: jnumed.119.238733. doi: 10.2967/jnumed.119.238733.
    PubMed     Abstract available


    February 2020
  13. SEBAN RD, Schwartz LH, Bonardel G, Dercle L, et al
    Diagnosis of Hyper-progressive Disease in Patients Treated with Checkpoint Inhibitors using (18)F-FDG PET/CT.
    J Nucl Med. 2020 Feb 21. pii: jnumed.120.242768. doi: 10.2967/jnumed.120.242768.
    PubMed    


  14. HUISMAN M, Niemeijer AL, Windhorst B, Schuit R, et al
    Quantification of PD-L1 expression with [(18)F]BMS-986192 PET/CT in patients with advanced stage non-small-cell lung cancer.
    J Nucl Med. 2020 Feb 14. pii: jnumed.119.240895. doi: 10.2967/jnumed.119.240895.
    PubMed     Abstract available


    December 2019
  15. CASTELLO A, Rossi S, Toschi L, Mazziotti E, et al
    Hyper-progressive Disease in Patients With Non-Small Cell Lung Cancer Treated With Checkpoint Inhibitors: The Role of (18)F-FDG PET/CT.
    J Nucl Med. 2019 Dec 20. pii: jnumed.119.237768. doi: 10.2967/jnumed.119.237768.
    PubMed     Abstract available


  16. ARNON-SHELEG E, Haberfeld O, Kremer R, Keidar Z, et al
    Head to head prospective comparison of quantitative lung scintigraphy and segment counting in predicting pulmonary function of lung cancer patients undergoing video-assisted thoracoscopic lobectomy.
    J Nucl Med. 2019 Dec 20. pii: jnumed.119.234526. doi: 10.2967/jnumed.119.234526.
    PubMed     Abstract available


  17. ROSSI G, Bauckneht M, Genova C, Rijavec E, et al
    Comparison between 18F-FDG-PET- and CT-based criteria in non-small cell lung cancer (NSCLC) patients treated with Nivolumab.
    J Nucl Med. 2019 Dec 5. pii: jnumed.119.233056. doi: 10.2967/jnumed.119.233056.
    PubMed     Abstract available


    November 2019
  18. DISSAUX G, Visvikis D, Do-Ano R, Pradier O, et al
    Pre-treatment (18)F-FDG PET/CT Radiomics predict local recurrence in patients treated with stereotactic radiotherapy for early-stage non-small cell lung cancer: a multicentric study.
    J Nucl Med. 2019 Nov 15. pii: jnumed.119.228106. doi: 10.2967/jnumed.119.228106.
    PubMed     Abstract available


    June 2019
  19. JREIGE M, Dunet V, Letovanec I, Prior JO, et al
    Pulmonary lymphangitic carcinomatosis: diagnostic performance of HRCT and (18)F-FDG-PET/CT in correlation to clinical pathologic outcome.
    J Nucl Med. 2019 Jun 21. pii: jnumed.119.229575. doi: 10.2967/jnumed.119.229575.
    PubMed     Abstract available


    February 2019
  20. XING Y, Chand G, Liu C, Cook GJR, et al
    Early phase I study of a (99m)Tc labeled anti-PD-L1 single domain antibody in SPECT/CT assessment of programmed death ligand-1 expression in non-small cell lung cancer.
    J Nucl Med. 2019 Feb 22. pii: jnumed.118.224170. doi: 10.2967/jnumed.118.224170.
    PubMed     Abstract available


    November 2018
  21. ZHUANG M, Vallez Garcia D, Kramer GM, Frings V, et al
    Variability and repeatability of quantitative uptake metrics in [(18)F]FDG PET/CT imaging of non-small cell lung cancer: impact of segmentation method, uptake interval, and reconstruction protocol.
    J Nucl Med. 2018 Nov 2. pii: jnumed.118.216028. doi: 10.2967/jnumed.118.216028.
    PubMed     Abstract available


    July 2018
  22. TURGEON GA, Iravani A, Akhurst T, Beaulieu A, et al
    What FDG-PET response-assessment method best predicts survival after curative-intent chemoradiation in non-small cell lung cancer (NSCLC): EORTC, PERCIST, Peter Mac or Deauville criteria?
    J Nucl Med. 2018 Jul 20. pii: jnumed.118.214148. doi: 10.2967/jnumed.118.214148.
    PubMed     Abstract available


  23. DE BRUYCKER S, Vangestel C, Van den Wyngaert T, Pauwels P, et al
    (18)F-HX4 Hypoxia PET Holds Promise as a Prognostic and Predictive Imaging Biomarker in a Lung Cancer Xenograft Model Treated with Metformin and Radiotherapy.
    J Nucl Med. 2018 Jul 6. pii: jnumed.118.212225. doi: 10.2967/jnumed.118.212225.
    PubMed     Abstract available


    May 2018
  24. HEINZMANN K, Nguyen QD, Honess DJ, Smith DM, et al
    Depicting changes in tumor biology in response to cetuximab mono- or combination therapy by apoptosis and proliferation imaging using (18)F-ICMT-11 and 3'-Deoxy-3'-[(18)F]Fluorothymidine ((18)F-FLT) PET.
    J Nucl Med. 2018 May 24. pii: jnumed.118.209304. doi: 10.2967/jnumed.118.209304.
    PubMed     Abstract available


  25. HAN Z, Xiao Y, Wang K, Yan J, et al
    Development of a Novel SPECT Tracer to Image c-Met Expression in Non-Small Cell Lung Cancer in a Human Tumor Xenograft.
    J Nucl Med. 2018 May 18. pii: jnumed.117.206730. doi: 10.2967/jnumed.117.206730.
    PubMed     Abstract available


    April 2018
  26. MCHUGH C, Thipparthi MR, Lawhorn-Crews JM, Polin L, et al
    Utilizing radiolabeled 3'-deoxy-3'-[(18)F]fluorothymidine with positron emission tomography to monitor the effect of dexamethasone on non-small cell lung cancer.
    J Nucl Med. 2018 Apr 19. pii: jnumed.117.207258. doi: 10.2967/jnumed.117.207258.
    PubMed     Abstract available


    November 2017
  27. OLIN A, Ladefoged CN, Langer NH, Keller SH, et al
    Reproducibility of MR-based Attenuation Maps in PET/MRI and the Impact on PET Quantification in Lung Cancer.
    J Nucl Med. 2017 Nov 9. pii: jnumed.117.198853. doi: 10.2967/jnumed.117.198853.
    PubMed     Abstract available


    June 2017
  28. KRAMER GM, Hoekstra OS, Boellaard R
    Reply: Repeatability of Quantitative Whole Body 18F-FDG PET/CT Uptake Measures in NSCLC Patients: Dynamic versus Test-Retest Design.
    J Nucl Med. 2017 Jun 15. pii: jnumed.117.195461. doi: 10.2967/jnumed.117.195461.
    PubMed    


  29. KRAMER GM, Frings V, Heijtel D, Smit EF, et al
    Parametric Method Performance for Dynamic 3'-Deoxy-3'-18F-Fluorothymidine PET/CT in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Carcinoma Patients Before and During Therapy.
    J Nucl Med. 2017;58:920-925.
    PubMed     Abstract available


    May 2017
  30. FLEDELIUS J, Winther-Larsen A, Khalil AA, Bylov CM, et al
    18F-FDG-PET/CT for very early response evaluation predicts CT response in Erlotinib treated NSCLC patients - A comparison of assessment methods.
    J Nucl Med. 2017 May 10. pii: jnumed.117.193003. doi: 10.2967/jnumed.117.193003.
    PubMed     Abstract available


  31. STEIGER S, Arvanitakis M, Sick B, Weder W, et al
    Analysis of prognostic values of various PET metrics in preoperative FDG PET for early stage bronchial carcinoma for progression free and overall survival: significantly increased glycolysis is a predictive factor.
    J Nucl Med. 2017 May 10. pii: jnumed.117.189894. doi: 10.2967/jnumed.117.189894.
    PubMed     Abstract available


    April 2017
  32. MORBELLI S, Alama A, Ferrarazzo G, Coco S, et al
    Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC): an 18F-FDG PET/CT study.
    J Nucl Med. 2017 Apr 27. pii: jnumed.117.193201. doi: 10.2967/jnumed.117.193201.
    PubMed     Abstract available


    March 2017
  33. WARNDERS FJ, Terwisscha van Scheltinga AG, Knuehl C, van Roy M, et al
    HER3 specific biodistribution and tumor uptake of 89Zr-MSB0010853 visualized by real-time and non-invasive PET imaging.
    J Nucl Med. 2017 Mar 30. pii: jnumed.116.181586. doi: 10.2967/jnumed.116.181586.
    PubMed     Abstract available


  34. USMANIJ EA, Natroshvili T, Timmer-Bonte JN, Oyen WJ, et al
    The predictive value of early in-treatment FDG-PET/CT response to chemotherapy in combination with bevacizumab in advanced non-squamous non-small cell lung cancer.
    J Nucl Med. 2017 Mar 23. pii: jnumed.116.185314. doi: 10.2967/jnumed.116.185314.
    PubMed     Abstract available


    January 2017
  35. HEKMAN MC, Rijpkema M, Bos D, Oosterwijk E, et al
    Detection of micrometastases using SPECT/fluorescence dual-modality imaging in a CEA-expressing tumor model.
    J Nucl Med. 2017 Jan 26. pii: jnumed.116.185470. doi: 10.2967/jnumed.116.185470.
    PubMed     Abstract available


    December 2016
  36. NOTNI J, Reich D, Maltsev OV, Kapp TG, et al
    In-vivo PET imaging of the "cancer integrin" alphavbeta6 using gallium-68 labelled cyclic RGD nonapeptides.
    J Nucl Med. 2016 Dec 15. pii: jnumed.116.182824.
    PubMed     Abstract available


    May 2016
  37. CYSOUW MC, Kramer GM, Hoekstra OS, Frings V, et al
    Accuracy and precision of partial volume correction in oncological PET/CT studies.
    J Nucl Med. 2016 May 26. pii: jnumed.116.173831.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: